News Image

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Provided By GlobeNewswire

Last update: Apr 11, 2025

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress

Read more at globenewswire.com

BIOCARDIA INC

NASDAQ:BCDA (9/5/2025, 8:00:01 PM)

After market: 2.06 0 (0%)

2.06

+0.02 (+0.98%)



Find more stocks in the Stock Screener

Follow ChartMill for more